Work

Growth hormone replacement therapy in childhood-onset craniopharyngioma

Year: 2025

Type: review

Abstract: Tumour- or treatment related growth hormone (GH) deficiency is often observed in children diagnosed or treated for childhood onset craniopharyngioma (cCP). Adequate and timely GH replacement therapy (GHRT) is important to improve growth velocity and final height during childhood. GHRT may be continued through adulthood due to its beneficial effects on metabolic health, bone health, mental health and quality of life. The current evidence suggests no increased risk for tumour progression or recurrence, secondary neoplasms or mortality in cCP patients receiving GHRT. In children with newly diagnosed cCP, GHRT may be initiated as early as three months after initial surgery to ameliorate linear growth and metabolic disturbances. The potential long-term effects of early initiation of GHRT as well GHRT with long-acting GH preparations are topics for future research.

Source: Best Practice & Research Clinical Endocrinology & Metabolism

DOI: 10.1016/j.beem.2025.101998

Authors: Laura van Iersel, Jiska van Schaik, Hanneke M. van Santen

Institutions: Erasmus MC, University Medical Center Utrecht, Erasmus MC - Sophia Children’s Hospital, Wilhelmina Children's Hospital, Princess Máxima Center

Language: English

Topic: Pituitary Gland Disorders and Treatments

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,450